BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized of 3.80 million shares for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized · last filed 2017-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2014-12-31 was 0.00 shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2014-09-30 was 0.00 shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2016 was 3.80M shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2014 was 3.75M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 12 month |
|---|---|---|---|---|
| 2016-12-31 | 3.80M shares 10-K · filed 2017-02-27 | |||
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2017-02-27 | 3.75M shares 10-K · filed 2017-02-27 | |
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | 3.75M shares 10-Q · filed 2014-11-07 | ||
| 2014-06-30 | 3.75M shares 10-Q · filed 2014-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |